SS-31

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain complexes and reducing reactive oxygen species while enhancing ATP synthesis.

Profile · 01

Overview

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain complexes and reducing reactive oxygen species while enhancing ATP synthesis. It received FDA accelerated approval in 2025 as the first treatment for Barth syndrome under the brand name Forzinity. Preclinical models show protective effects in heart failure, neurodegenerative disease, and age-related muscle atrophy, while Phase II trials in heart failure and primary mitochondrial myopathy did not meet primary efficacy endpoints. This protocol presents a once-daily subcutaneous approach using practical dilution for clear insulin-syringe measurements.

At a Glance

Goal
Support mitochondrial function, enhance ATP production, and reduce oxidative stress
Categories
Mitochondrial SupportAnti-AgingCellular EnergyNeuroprotection
Synergistic
CoQ10 · NAD+ precursors (NMN/NR) · PQQ · Alpha-Lipoic Acid
Profile · 02

Protocol

Suggested daily titration approach based on clinical trial protocols.

Typical daily range
5–10 mg once daily (gradual titration)
Start
5 mg daily for Weeks 1–2 to assess individual tolerance
Target
10 mg daily by Week 3 (most common clinical trial dose)
Frequency
Once per day (subcutaneous)
Cycle Length
8–12 weeks; limited data exists beyond 12 weeks
Timing
Any consistent time; rotate injection sites to prevent tissue irritation
Route
Subcutaneous
Cycle
8–12 weeks on, 4 weeks off

Inject once daily subcutaneously at a consistent time. Clinical trials have not extensively evaluated SS-31 beyond 12 weeks; extended use requires careful monitoring. Dosing is based on clinical trial protocols; advanced dosing is described below. An advanced/aggressive approach (Weeks 1–2 at 5 mg, Weeks 3–4 at 10 mg, Weeks 5–8 at 15 mg, Weeks 9–12 optional at 20 mg) is described in clinical trial protocols for severe mitochondrial conditions and should only be pursued under medical supervision; doses above 10 mg require splitting into two separate subcutaneous injections at different sites.

Dose progression

Weeks 1–2
5,000 mcg (5 mg)
Weeks 3–8
10,000 mcg (10 mg)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How SS-31 works.

SS-31 (elamipretide) is a cell-permeable tetrapeptide with a unique mechanism targeting mitochondrial dysfunction. The peptide selectively accumulates in the inner mitochondrial membrane where it binds to cardiolipin, a specialized phospholipid essential for organizing electron transport chain supercomplexes and maintaining cristae structure. By stabilizing cardiolipin-protein interactions, SS-31 optimizes electron transport efficiency, reduces pathological reactive oxygen species generation, and enhances ATP synthesis in metabolically active tissues. Preclinical research demonstrated protective effects against mitochondrial dysfunction across multiple disease models including heart failure, ischemia-reperfusion injury, neurodegeneration, chronic kidney disease, and age-related muscle atrophy. In human clinical trials, SS-31 showed favorable safety and tolerability profiles with no dose-limiting toxicities. While Phase II trials in heart failure (PROGRESS-HF) and primary mitochondrial myopathy (MMPOWER-2) did not meet primary efficacy endpoints, the TAZPOWER trial in Barth syndrome demonstrated significant improvements in muscle strength and six-minute walk distance, leading to FDA accelerated approval in 2025.

Science · 02

Effects

Observations from clinical or preclinical literature.

Stabilizes mitochondrial membranes and optimizes electron transport chain function
Enhances ATP production and reduces pathological reactive oxygen species in metabolically active tissues
Demonstrated functional improvements in Barth syndrome patients (increased muscle strength, improved exercise capacity)
Shows protective effects in preclinical models of heart failure, neurodegenerative disease, and age-related muscle atrophy
Does not significantly alter blood pressure, heart rate, or standard laboratory parameters in clinical trials
Injection-site reactions (most common): mild-to-moderate redness, itching, or transient discomfort; typically resolves within hours
Approximately 80% of patients in clinical trials experienced mild injection-site reactions
No dose-limiting toxicities or serious adverse events directly attributed to SS-31 in published trials
Long-term safety data beyond 12 weeks remains limited; extended use requires monitoring
Science · 03

Caution

Not recommended during pregnancy or breastfeeding (no safety data available)
Use with caution in individuals with severe renal or hepatic impairment (limited data)
Consult a healthcare provider before use if taking medications that affect mitochondrial function
SS-31 is currently FDA-approved only for Barth syndrome; use for other conditions remains investigational

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

CoQ10 (Ubiquinol)
Essential electron carrier in the mitochondrial electron transport chain; supports the same pathway SS-31 targets.
B-Vitamins (B1, B2, B3, B5)
Critical cofactors for mitochondrial energy metabolism and the citric acid cycle.
Magnesium
Supports ATP synthesis and over 300 enzymatic processes including mitochondrial function.
Alpha-Lipoic Acid
Mitochondrial antioxidant that supports energy metabolism and reduces oxidative stress.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Emphasize mitochondrial cofactors including B-vitamins, CoQ10, magnesium, and alpha-lipoic acid; maintain adequate protein intake to support muscle maintenance
Combine resistance training with aerobic activity to stimulate mitochondrial biogenesis and enhance oxidative capacity; tailor intensity to individual tolerance
Prioritize 7–9 hours of quality sleep to support cellular repair processes and optimize mitochondrial turnover through autophagy
Chronic stress increases oxidative burden; incorporate stress-reduction practices such as meditation, breathwork, or yoga
Minimize exposure to substances that impair mitochondrial function, including excessive alcohol, certain medications (when possible), and environmental toxins
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Energy levels and fatigue — monitor daily subjective energy to gauge mitochondrial support response
  2. Exercise capacity and recovery — track workout performance and post-exercise recovery time
  3. Injection-site reactions — note any redness, itching, or discomfort to guide site rotation
  4. Cognitive function and mental clarity — mitochondrial health influences brain function; track focus and clarity
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

Lactate / Pyruvate ratio
Marker of mitochondrial function; elevated ratio may indicate mitochondrial dysfunction.
CoQ10 levels
Assess baseline and ensure adequate cofactor support.
CRP (C-Reactive Protein)
General inflammation marker; track before and during protocol.
CBC (Complete Blood Count)
Monitor overall health during peptide use.
CMP (Comprehensive Metabolic Panel)
Assess liver and kidney function during protocol.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 50 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and injection site with alcohol swabs; allow to air-dry completely (30–60 seconds) before proceeding
Use new sterile insulin syringe for each injection; draw prescribed volume from refrigerated vial; remove any visible air bubbles by gently tapping syringe
Pinch a fold of skin (approximately 1–2 inches); insert needle at 45–90° depending on subcutaneous tissue thickness (90° for most adults; 45° if very lean)
Do not aspirate for subcutaneous injections; inject slowly and steadily over 3–5 seconds; wait 5–10 seconds before withdrawing needle to minimize leakage
Rotate systematically between injection sites (abdomen at least 2 inches from navel, outer thighs, upper arms, upper buttocks) to prevent lipohypertrophy and local irritation
Apply gentle pressure with clean alcohol swab or cotton ball for a few seconds; do not massage site vigorously
Immediately place used syringes in designated sharps container; never recap needles or dispose in regular trash

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use new sterile insulin syringes for each injection; dispose in sharps container immediately after use
Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy
Inject slowly over several seconds; wait briefly before withdrawing needle to prevent leakage
Mild injection-site reactions (redness, itching, transient discomfort) are the most common side effects reported in clinical trials; typically resolve within hours
Document daily dose, injection site, and any adverse reactions to maintain consistency and identify patterns
For doses requiring split injections (≥15 mg), space injections at least 2 inches apart on different body regions
Reference · 02

References

  1. International Journal of Molecular Sciences (MDPI)
    Elamipretide: comprehensive review of structure, mechanism of action, and therapeutic potential.
    https://www.mdpi.com/1422-0067
  2. British Journal of Pharmacology (PMC)
    Cardiolipin-binding mechanism and mitochondrial membrane stabilization by SS-31.
    https://pmc.ncbi.nlm.nih.gov
  3. U.S. Food & Drug Administration (FDA)
    FDA grants accelerated approval to elamipretide (Forzinity) as first treatment for Barth syndrome (2025).
    https://www.fda.gov
  4. Journal of the American College of Cardiology (JACC)
    PROGRESS-HF trial: safety and tolerability of elamipretide in heart failure patients.
    https://www.jacc.org
  5. Neurology (AAN Journals)
    MMPOWER-2 trial: elamipretide in primary mitochondrial myopathy.
    https://www.neurology.org
  6. Genetics in Medicine (Nature)
    TAZPOWER trial: efficacy and safety of elamipretide in Barth syndrome.
    https://www.nature.com/gim
  7. Biochimica et Biophysica Acta (BBA) – Bioenergetics
    Cardiolipin remodeling and cristae structure: role in mitochondrial function.
    https://www.sciencedirect.com/journal/bba-bioenergetics
  8. Journal of Cardiovascular Pharmacology (PMC)
    SS-31 reduces oxidative stress and improves mitochondrial bioenergetics.
    https://pmc.ncbi.nlm.nih.gov
  9. Alzheimer's Drug Discovery Foundation
    Cognitive Vitality Report: SS-31 (elamipretide) preclinical and clinical overview.
    https://www.alzdiscovery.org
  10. Orphanet Journal of Rare Diseases (PMC)
    Barth syndrome: clinical presentation, diagnosis, and emerging therapies.
    https://pmc.ncbi.nlm.nih.gov
  11. CDC
    Vaccine administration: subcutaneous injection technique (angle, site selection, no aspiration).
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  12. Johns Hopkins Arthritis Center
    Patient guide: how to give a subcutaneous injection (step-by-step instructions).
    https://www.hopkinsarthritis.org/patient-corner/how-to-give-a-subcutaneous-injection/
  13. NCBI Bookshelf (StatPearls)
    Best practices for injection: aseptic technique, preparation, and administration.
    https://www.ncbi.nlm.nih.gov/books/NBK138495/
  14. Subcutaneous Drug Injection Review (PMC)
    Pharmacologic considerations of the subcutaneous route.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/
On this page